title: Effects of combined levosimendan and vasopressin on pulmonary function in porcine septic shock.
abstract: This study aims to determine whether levosimendan combined with arginine vasopressin infusion supplemented with norepinephrine can improve hemodynamics and pulmonary dysfunction. The study was tested in a fecal peritonitis-induced septic shock model, we observed that levosimendan combined with arginine vasopressin supplemented with norepinephrine therapy resulted in lower mean pulmonary artery pressure, lactate concentrations, arterial total nitrate/nitrite, and high-mobility group box 1 levels; decreased lung wet/dry ratio, and pulmonary levels of interleukin-6, total histological scores, and improved pulmonary gas exchange when compared with norepinephrine group. Levosimendan combined with arginine vasopressin supplemented with norepinephrine infusion shows potential benefit in sepsis-induced acute lung injury by decreasing mean pulmonary artery pressure and attenuating inflammatory responses in the lung compared to norepinephrine infusion alone.
authors.affiliation: Department of Anesthesiology, Jinling Hospital, School of Medicine, Nanjing University, 305 East Zhongshan Road, Nanjing 210002, China.
authors.forename: Muhuo
authors.initials: M
authors.lastname: Ji
authors.forename: Renqi
authors.initials: R
authors.lastname: Li
authors.forename: Guo-min
authors.initials: GM
authors.lastname: Li
authors.forename: Yunxia
authors.initials: Y
authors.lastname: Fan
authors.forename: Lin
authors.initials: L
authors.lastname: Dong
authors.forename: Jianjun
authors.initials: J
authors.lastname: Yang
authors.forename: Yong G
authors.initials: YG
authors.lastname: Peng
authors.forename: Jing
authors.initials: J
authors.lastname: Wu
mesh_terms: D000818:Animals; D001127:Arginine Vasopressin / Q000494:pharmacology / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D004359:Drug Therapy, Combination; D005260:Female; D024742:HMG-Box Domains; D006439:Hemodynamics / Q000187:drug effects; D006835:Hydrazones / Q000494:pharmacology / Q000627:therapeutic use*; D007249:Inflammation / Q000188:drug therapy; D015850:Interleukin-6 / Q000032:analysis; D019344:Lactic Acid / Q000097:blood; D008168:Lung / Q000187:drug effects* / Q000502:physiology; D009566:Nitrates / Q000097:blood; D009573:Nitrites / Q000097:blood; D009638:Norepinephrine / Q000494:pharmacology / Q000627:therapeutic use*; D010538:Peritonitis / Q000139:chemically induced / Q000188:drug therapy; D011651:Pulmonary Artery / Q000187:drug effects / Q000473:pathology; D011659:Pulmonary Gas Exchange / Q000187:drug effects; D011724:Pyridazines / Q000494:pharmacology / Q000627:therapeutic use*; D011897:Random Allocation; D012143:Respiratory Physiological Phenomena / Q000187:drug effects*; D012772:Shock, Septic / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D000077464:Simendan; D013552:Swine
chemical_list: D006835:Hydrazones; D015850:Interleukin-6; D009566:Nitrates; D009573:Nitrites; D011724:Pyridazines; D001127:Arginine Vasopressin; D019344:Lactic Acid; D000077464:Simendan; D009638:Norepinephrine